Five day intermittent vs seven day continuous 2-chlorodeoxyadenosine infusion for the treatment of hairy cell leukemia. A study by Italian Group for the Hairy Cell Leukemia

التفاصيل البيبلوغرافية
العنوان: Five day intermittent vs seven day continuous 2-chlorodeoxyadenosine infusion for the treatment of hairy cell leukemia. A study by Italian Group for the Hairy Cell Leukemia
المؤلفون: E E, Damasio, L, Resegotti, B, Masoudi, R, Bruni, R, Cerri, A, Isaza, M, Clavio, M, Risso, E, Rossi, M, Spriano, M, Truini
المصدر: Recenti progressi in medicina. 89(2)
سنة النشر: 1998
مصطلحات موضوعية: Adult, Aged, 80 and over, Male, Leukemia, Hairy Cell, Time Factors, Antibodies, Monoclonal, Antineoplastic Agents, Middle Aged, Immunohistochemistry, Drug Administration Schedule, Evaluation Studies as Topic, Cladribine, Humans, Female, Infusions, Intravenous, Aged, Follow-Up Studies
الوصف: The new purine-analogue 2-chlorodeoxyadenosine (2-CdA) has proved to induce an high CR rate and a long lasting disease free survival. In this study we compare the efficacy and toxicity of 2-CdA employed in two different schedules (A and B). Forty-one patients have been enrolled from 1994: 22 p. (group A) were treated with a single cycle of 2-CdA given as two hour i.v. infusion on 5 consecutive days (0.15 mg/kg/die); while 19 p. (group B) with continuous i.v. infusion for 7 consecutive days (0.10 mg/kg/die). Response criteria were those proposed by NCI. The Hairy Cell Index (HCI) was calculated using DBA44 MoAb. At three months, the responses in group A (19/22) were: 5 CR (26.3%), 6 GPR (31.5%), 5 PR and 3 NR.; in group B (17/19): 6 CR (35.3%), 3 GPR (17.6%), 4 PR and 4 NR. Overall response at six months was respectively 84.2% and 76.5%. At six months the responses were: in group A (18/22): 9 CR (50%), 4 GPR (22.2%), 3 PR, 2 NR; in group B (16/19): 4 CR (25%), 6 GPR (37.5%), 3 PR, 3 NR. Overall response at 6 months was respectively 88.8% (group A) and 81.2% (group B). The 5 day intermittent schedule appears efficient, well tolerated and suitable for out-patient treatment. DBA44 MoAb appears useful to better define the HCI and to distinguish CR from GPR.
تدمد: 0034-1193
URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::f338382949ad0a8c7375fd6ca64640f7
https://pubmed.ncbi.nlm.nih.gov/9558908
رقم الأكسشن: edsair.pmid..........f338382949ad0a8c7375fd6ca64640f7
قاعدة البيانات: OpenAIRE